ARTICLES IN THREE SENTENCES
B-cell maturation antigen (BCMA) is an attractive tumor-associated antigen to be targeted by chimeric antigen receptor (CAR) T cells in multiple myeloma. Ortal Harush and colleagues aimed to assess the function and optimal configuration of different BCMA-specific CAR T cells. Their study led to the identification of a highly efficient BCMA-specific CAR T cell, namely H8BB, which displayed superior anti-tumoral activity in vitro and long-term in vivo efficacy.
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
Gain/amplification of 1q21 (1q21+) is one of the most common chromosomal abnormalities in multiple myeloma (MM). In the phase III studies ICARIA-MM and IKEMA, the addition of the anti-CD38 monoclonal antibody isatuximab (Isa) to the backbone of pomalidomide–dexamethasone (Pd) or carfilzomib–dexamethasone (Kd) improved progression-free survival among patients with relapsed/refractory MM. Martin and colleagues examined four subgroups of patients from ICARIA-MM and IKEMA: patients with 1q21+, isolated 1q21+, gain(1q21), and amp(1q21), and showed a clear benefit of Isa-based combinations in all 1q21+ disease subgroups.
Fc galactosylation of anti-platelet human IgG1 alloantibodies enhances complement activation on platelets
Approximately 20% of patients receiving multiple platelet transfusions develop platelet alloantibodies, which can be directed against human leukocyte antigens (HLA) and human platelet antigens (HPA), resulting in platelet refractoriness. Van Osch and colleagues produced recombinant glycoengineered anti-HLA and antiHPA-1a monoclonal antibodies with varying Fc galactosylation and sialylation levels and studied their ability to activate the classical complement pathway. Their work provides more insight into the mechanisms of classical complement activation by anti-platelet antibodies, which can be formed as a consequence of alloimmunization.
Acquired pure red cell aplasia (PRCA) is a heterogenous entity. Management of PRCA can be challenging, especially in cases without a clear etiology, and treatment recommendations are based on case series and expert opinion. Gangat and colleagues describe a 74-year-old female with a 10-year history of treatment-refractory idiopathic acquired PRCA who had a rapid and sustained response to daratumumab.
TAKE ADVANTAGE FROM HAEMATOLOGICA